QV Investors Inc. Reduces Stock Holdings in Merck & Co., Inc. $MRK

Posted by Francis Steltz on Aug 15th, 2026

QV Investors Inc. lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 85.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 18,367 shares of the company’s stock after selling 110,570 shares during the quarter. QV Investors Inc.’s holdings in Merck & Co., Inc. were worth $2,360,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of MRK. Vanguard Group Inc. boosted its stake in Merck & Co., Inc. by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after buying an additional 2,185,853 shares during the period. State Street Corp raised its stake in shares of Merck & Co., Inc. by 1.6% in the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after acquiring an additional 1,859,990 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after purchasing an additional 249,110 shares during the period. Finally, Morgan Stanley grew its holdings in Merck & Co., Inc. by 0.8% during the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock valued at $4,731,018,000 after purchasing an additional 359,486 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. The trade was a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP David R. Maraldo sold 18,706 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Trading Up 0.2%

NYSE MRK opened at $135.78 on Friday. The company’s 50-day moving average price is $125.54 and its 200-day moving average price is $119.94. The company has a current ratio of 1.32, a quick ratio of 1.06 and a debt-to-equity ratio of 1.22. The stock has a market cap of $334.98 billion, a PE ratio of 108.62, a PEG ratio of 5.85 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.97.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the firm posted $2.13 EPS. The firm’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MRK. Argus increased their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley boosted their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target on the stock in a report on Wednesday. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Fifteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $135.50.

Get Our Latest Stock Analysis on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.